8-K: BiomX Inc. Cancels Shares to Comply with NYSE Listing Rules

BiomX Inc. has cancelled 1,013,637 restricted shares to regain compliance with NYSE American listing rules pending shareholder approval of a prior acquisition.

Summary

• BiomX Inc. has cancelled 1,013,637 restricted shares of its common stock that were issued on June 2, 2026.
• These shares were issued to three assignees of Mandragola Ltd. upon the partial conversion of a convertible promissory note related to a prior acquisition.
• The cancellation was necessary to regain compliance with Section 712 of the NYSE American Company Guide, which requires shareholder approval for issuances of stock in connection with acquisitions where the issued stock equals 20% or more of outstanding shares.
• The company intends to seek shareholder approval for these issuances at a future stockholder meeting.
• There is no guarantee that shareholder approval will be obtained.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a negative development due to the compliance issue and the uncertainty of shareholder approval, although the proactive cancellation mitigates immediate delisting risk.

Positives

• The company has proactively addressed a potential NYSE American listing compliance issue by cancelling the shares.
• The cancellation of shares returns them to the company's treasury, no longer impacting outstanding share counts.
• The company is taking steps to seek shareholder approval, demonstrating a commitment to corporate governance and compliance.

Negatives

• The company faces uncertainty regarding obtaining the necessary shareholder approval for the related transactions.
• The NYSE American may take further action regarding the listing of the company's common stock.
• The cancellation of shares indicates a potential misstep in the initial acquisition and financing process.

Risks

• The risk that the required stockholder approval may not be obtained on the anticipated timeline or at all.
• The risk that the NYSE American may take further action with respect to the listing of the company's common stock.
• Potential for continued scrutiny from the NYSE American regarding listing standards.

Future Outlook

The company intends to seek stockholder approval for the issuances in the Related Transactions at a future meeting. There is no assurance that this approval will be obtained, and the NYSE American may take further action regarding the company's stock listing.

Management Comments

• The company intends to seek stockholder approval of the issuances in the Related Transactions under Section 712 of the NYSE American Company Guide at a meeting of its stockholders.
• There can be no assurance that the Company will obtain such approval.

Industry Context

StockSavvy.ai notes that this filing highlights the critical importance of adhering to exchange listing rules, particularly concerning share issuances related to acquisitions. Failure to comply can lead to delisting risks, impacting investor confidence and market liquidity.

Corporate Governance

Related Party Transactions

• Acquisition of a 60% interest in Dr. Frucht Systems Ltd. from Mandragola Ltd.
• Revolving line of credit of up to $2,000,000 with Mandragola Ltd.
• Issuance of 1,013,637 restricted shares to assignees of Mandragola Ltd. upon partial conversion of a convertible promissory note.

Stakeholder Impact

• Shareholders: Potential dilution if approval is granted, but also risk of delisting if compliance issues are not resolved.
• Creditors: The company's ability to maintain its listing on NYSE American is crucial for its financial stability and access to capital.

Next Steps

• Seek stockholder approval for the issuances in the Related Transactions at a meeting of its stockholders.
• Regain and maintain compliance with the continued listing standards of NYSE American.

Key Dates

Recommendation

The company has taken a necessary step to address a NYSE listing compliance issue, but the uncertainty surrounding shareholder approval for the underlying transactions introduces significant risk. Investors should hold positions until further clarity on shareholder approval and potential NYSE actions is available.

Keywords

BiomX Inc., Form 8-K, NYSE American, Shareholder Approval, Acquisition, Convertible Note, Stock Cancellation, Listing Compliance, Corporate Governance